Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo Nordisk L | London | Healthcare | Pharmaceuticals | £398.80B | 40.3x | 1.16 | 9,011.44 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie Inc | London | Healthcare | Pharmaceuticals | £261.43B | 64.8x | -1.83 | 16,268.32 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck & Co Inc | London | Healthcare | Pharmaceuticals | £215.91B | 20.5x | 0.06 | 8,492.82 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding | London | Healthcare | Pharmaceuticals | £209.48B | 22.2x | -6.21 | 26,183.79 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | London | Healthcare | Pharmaceuticals | £209.48B | 22.2x | -6.21 | 24,059.46 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | London | Healthcare | Pharmaceuticals | £184.08B | 37.3x | 8.67 | 11,850 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.7% Upside | Upgrade to Pro+ | |
Novartis | London | Healthcare | Pharmaceuticals | £180.37B | 14.7x | 0.2 | 8,911.54 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbott Laboratories L | London | Healthcare | Healthcare Equipment & Supplies | £155.71B | 36.9x | 4.38 | 8,942.70 | 5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi L | London | Healthcare | Pharmaceuticals | £105.37B | 14.3x | -0.58 | 8,391.39 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Essilor International | London | Healthcare | Healthcare Equipment & Supplies | £82.09B | 42.5x | -12.13 | 18,022.64 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | London | Healthcare | Pharmaceuticals | £61B | 15.1x | -0.2 | 1,494 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.8% Upside | Upgrade to Pro+ | |
Merck KGaA | London | Healthcare | Pharmaceuticals | £56.78B | 25.9x | -1.75 | 13,109.87 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Siemens Healthineers | London | Healthcare | Healthcare Equipment & Supplies | £48.45B | 31.6x | 1.85 | 4,334.10 | -9.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HALEON | London | Healthcare | Pharmaceuticals | £34.60B | 33.2x | -2.78 | 381.10 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.7% Upside | Upgrade to Pro+ | |
Lonza Group | London | Healthcare | Biotechnology & Medical Research | £34.52B | 72.6x | -1.37 | 47,666.56 | -7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
UCB L | London | Healthcare | Pharmaceuticals | £27.47B | 137.7x | -4.97 | 14,470.64 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
arGEN X BV | London | Healthcare | Biotechnology & Medical Research | £24.88B | -157.2x | -3.04 | 42,011.13 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Koninklijke Philips | London | Healthcare | Healthcare Equipment & Supplies | £23.30B | -65.2x | -0.63 | 2,485.56 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Coloplast AS | London | Healthcare | Healthcare Equipment & Supplies | £22.24B | 40.1x | -21.04 | 9,946.44 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer L | London | Healthcare | Pharmaceuticals | £21.80B | -20.6x | 0.11 | 2,211.24 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen | London | Healthcare | Pharmaceuticals | £21.50B | 24.2x | -0.42 | 14,714.51 | 100,000% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sonova Holding | London | Healthcare | Healthcare Equipment & Supplies | £16.85B | 31.7x | -4.99 | 28,565.34 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Fresenius SE Co KGaA | London | Healthcare | Healthcare Providers & Services | £15.86B | -17.2x | -0.13 | 2,823.25 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sandoz | London | Healthcare | Pharmaceuticals | £14.65B | -2,379.2x | 23.42 | 3,278.30 | 29.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | London | Healthcare | Biotechnology & Medical Research | £11.36B | 18.9x | 0.92 | 17,895.54 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Smith & Nephew | London | Healthcare | Healthcare Equipment & Supplies | £9.46B | 40.6x | 1.02 | 1,084.50 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.4% Upside | Upgrade to Pro+ | |
Recordati Industria | London | Healthcare | Pharmaceuticals | £9.16B | 28.6x | -71.95 | 4,502.53 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Fresenius Medical Care | London | Healthcare | Healthcare Providers & Services | £9.07B | 20.5x | -1.82 | 3,088.40 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific SE FRA | London | Healthcare | Healthcare Providers & Services | £8.89B | 33.3x | -1.59 | 4,627.60 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ipsen L | London | Healthcare | Pharmaceuticals | £7.88B | 13.9x | 0.28 | 9,584.56 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |